Table 1.
Characteristics of all patients.
Table 2.
Association of different genotypes with clinicopathological characteristics in 430 patients (ALK rearrangement results based on FISH detection).
Figure 1.
Detection of ALK rearrangements using Fluorescent in situ hybridization (FISH) (1000×).
(A) An ALK-negative case. (B) An ALK-positive case with split signal pattern. (C) An ALK-positive case with isolated red signal pattern.
Figure 2.
Detection of ALK rearrangements using Ventana immunohistochemistry (IHC) (200×).
(A) An ALK-negative case without cytoplasmic staining. (B) An EML4-ALK-positive case with strong granular cytoplasmic staining. (C) A KIF5B-ALK-positive case identified by RT-PCR with strong granular cytoplasmic staining.
Table 3.
Details of 11 patients with a co-mutation of EGFR and ALK by RT-PCR.
Table 4.
Comparison of FISH and IHC in 430 patients and comparison of FISH and RT-PCR on detecting ALK rearrangements among 200 patients.
Figure 3.
Progression-free survival (PFS) and overall survival (OS) among ALK-positive patients, patients who have EGFR activating mutations and wild type both ALK and EGFR (WT/WT).
(A) PFS for patients receiving the first-line chemotherapy harboring ALK rearrangements, EGFR activating mutations, and WT/WT. (B) PFS for patients receiving EGFR TKIs harboring ALK rearrangements, EGFR activating mutations, and WT/WT. (C) OS for patients harboring ALK rearrangements, EGFR activating mutations, and WT/WT.
Table 5.
Treatment response and PFS according to different genotypes in patients with recurrent or advanced diseases.
Table 6.
Univariate and multivariate analysis for overall survival.